Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- BLDP +13%, (sees FY17 revs above consensus; provides comments on short-seller report), CISN +5%, WRK +3.5%, LMT +2.6%, STX +2.1%, CFFN +1%, AHGP +0.8%
M&A news:
- DPS +37.9% (Dr Pepper Snapple and Keurig Green Mountain enter into a merger agreement to create Keurig Dr Pepper; DPS shareholders will receive $103.75 per share in a special cash dividend and retain 13% of the combined company)
- ABLX +19.6% (Sanofi to acquire Ablynx for €3.9 bln)
- INAP +8.3% (to acquire SingleHop for $132 mln)
- AVP +5.8% (activists want company to consider sale, according to WSJ)
- CASI +4.1% (acquired a portfolio of 25 U.S. FDA-approved abbreviated new drug applications)
Other news:
- PTCT +12.4% (presents preliminary data from FIREFISH trial in Type 1 SMA )
- FOLD +1.9% (announces the CDR has posted the CDEC's positive recommendation of Galafold (migalastat) for listing with provincial drug formularies)
- PTX +1.2% (enters into a settlement agreement with Actavis Laboratories resolving patent litigation related to Zohydro ER )
- LOW +0.4% (authorized a new $5 billion repurchase program)
Analyst comments:
- ZYNE +5.2% (initiated with a Buy at Ladenburg Thalmann; tgt $25.50)
- MOMO +3.2% (upgraded to Overweight at JPMorgan)
- AGN +1.3% (upgraded to Overweight from Equal Weight at Barclays)